Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
Saved in:
| Title: | Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials. |
|---|---|
| Authors: | Armstrong, April W.1, Augustin, Matthias2, Beaumont, Jennifer L.3, Pham, Tan P.3, Hudgens, Stacie3, Gordon, Kenneth B.4, Zhuo, Joe5 joe.zhuo@bms.com, Becker, Brandon5, Zhong, Yichen5, Kisa, Renata M.5, Banerjee, Subhashis5, Papp, Kim A.6,7 |
| Source: | Dermatology & Therapy. Aug2024, Vol. 14 Issue 8, p2235-2248. 14p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
